SCHEMBL4658155

SCHEMBL4658155

NC(=NC(=O)c1ccccc1Cl)N1CCc2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 1/20 0.62
KMT2A Q03164 2/20 0.53
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 1/20 0.48
TSHR P16473 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 2/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.48
NOTUM Q6P988 1/20 0.48
LMNA P02545 1/20 0.47
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
SPR P35270 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4656775 0.91 SCN2A (0.59) SCN2AKMT2ANPC1RAB9AL3MBTL1
SCHEMBL4629264 0.88 SCN2A (0.58) SCN2AKMT2ANPC1RAB9AL3MBTL1
SCHEMBL4659179 0.87 SCN2A (0.62) SCN2AKMT2ANPC1RAB9AL3MBTL1
SCHEMBL4628733 0.82 SCN2A (0.77) SCN2AKMT2ANPC1RAB9AMEN1
SCHEMBL4628750 0.81 SCN2A (0.69) SCN2AKMT2ANPC1RAB9AMEN1
SCHEMBL4656525 0.80 KMT2A (0.55) SCN2AKMT2ANPC1RAB9AMEN1
SCHEMBL28163452 0.79 NPC1 (0.68) KMT2ANPC1RAB9AL3MBTL1TSHR
SCHEMBL6774952 0.79 MAPT (0.55) SCN2AKMT2ANPC1RAB9AMEN1
SCHEMBL4629262 0.77 SCN2A (1.00) SCN2AKMT2ANPC1RAB9AL3MBTL1
SCHEMBL6776139 0.76 MAPT (0.56) SCN2AKMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed
EP-1032556-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE INC (US) 2005-02-02 EP disclosed
EP-1032556-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-09-06 EP disclosed
WO-1999020599-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885KMT2A 3245/4885NPC1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.